Principia Biopharma Inc

Principia Biopharma — Technical Presentation (December 2019)

14 slides from Principia Biopharma's technical presentation, Dec 9, 2019

  1. Slide 1: Phase I/II, Open-Label, Adaptive Study of Oral BTK Inhibitor PRN1008 in Relapsed/Refractory ITP

    Exhibit 99.2 Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients With Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia 1 2 3 4 5 6 David J. Kuter, Ralph V. Boccia, Eun-Ju Lee, Merlin Efraim, Nikolay Tzvetkov, Jiri Mayer, 7 8 9 10 11 Mar

  2. Slide 2: Immune Thrombocytopenia (ITP)

    Immune Thrombocytopenia (ITP) § ITP is characterized by immune-mediated platelet destruction and impairment of platelet production, leading to thrombocytopenia, a predisposition to bleeding, and adverse impact on patient quality of life (QOL) § Current therapies for adults with ITP include − Initial

  3. Slide 3: Bruton Tyrosine Kinase (BTK) Inhibition Mechanisms for Targeting Drivers of Immune-Mediated Disease

    Bruton Tyrosine Kinase (BTK) Inhibition Mechanisms for 1,2 Targeting Drivers of Immune-Mediated Disease BTK BTK BTK BTK BTK BTK B cells, Monocyte, Mast cells, Neutrophils T cells plasma cells macrophage basophils Blocks B-cell receptor Blocks IgG-mediated FcγR Blocks IgE-mediated FcεR Inhibits activ

  4. Slide 4: PRN1008: Reversible, Covalent Inhibitor Selects for BTK

    PRN1008: Reversible, Covalent Inhibitor Selects for BTK High Occupancy, Low Systemic Exposure for Use in Immunology Ibrutinib PRN1008 Kinase Selectivity Kinase Selectivity PRN1008 has improved kinase selectivity In a 251-kinase panel, >90% inhibition was achieved in § 21 kinases for ibrutinib (1 µM)

  5. Slide 5: PRN1008: No Impact on Platelet Function

    PRN1008: No Impact on Platelet Function Ibrutinib has significant effects PRN1008 does not alter platelet aggregation in on platelet aggregation in HV blood taken from healthy volunteers or ITP patients 1 µM Ibrutinib − 1 µM PRN1008 − 1 µM PRN1008 − Healthy Volunteers Healthy Volunteers ITP Patients

  6. Slide 6: Adaptive, Open-Label, Dose-Finding, Phase I/II Study of PRN1008 in Relapsed/Refractory ITP

    Adaptive, Open-Label, Dose-Finding, Phase I/II Study of PRN1008 in Relapsed/Refractory Immune Thrombocytopenia (ITP) Key inclusion criteria (N ≤ 40) Intrapatient dose escalation of PRN1008 § PRN1008 doses* (24 wk): 200 and 400 mg qd § Adults age 18-80 y 300 and 400 mg bid § Relapsed/refractory ITP §

  7. Slide 7: Key Study Endpoints

    Key Study Endpoints Primary Endpoint Two or more consecutive platelet counts ≥ 50,000/μL without requiring rescue medication Additional endpoints § Any 2 platelet counts ≥ 50,000/µL § Platelet responses over time, by duration of treatment, and clinical benefit (≥ 30,000/μL) § Stable response - defin

  8. Slide 8: Patient Demographics and Prior ITP Therapy

    Patient Demographics and Prior ITP Therapy Demographics N = 31 Prior ITP Therapy N = 31 Median age, y (range) 50 (21-74) Median number of prior ITP therapies 6 (1-41) (range) Female, n (%) 18 (58) Splenectomy, n (%) 8 (26) ITP classification, n (%) Prior ITP therapies, n (%) Primary ITP 29 (94) Cort

  9. Slide 9: Summary of Platelet Response by Treatment Duration and Dose

    Summary of Platelet Response by Treatment Duration and Dose Patients Achieving 9 Platelet Counts ≥ 50 × 10 /L (80% CI) Treatment Duration and Dose Primary Endpoint* Any 2 4 of Final 8 (data cut-off 13Nov2019) 2 consecutive All patients enrolled 39% (28%-50%) 45% (34%-57%) 29% (20%-40%) (N = 31) ≥ 4

  10. Slide 10: Individual Platelet Counts By Dose Levels Over Time to Date

    Individual Platelet Counts By Dose Levels Over Time to Date Responders* (colored dots/lines) Non-responders (gray) Data cut-off 13Nov2019. *Patients who achieved ≥ 50,000/μL platelet counts at least once. 10Individual Platelet Counts By Dose Levels Over Time to Date Responders* (colored dots/lines)

  11. Slide 11: Subset Analyses of Primary Platelet Responses

    Subset Analyses of Primary Platelet Responses* Primary Response (N=31)§ Overall, 39% of patients met the primary endpoint 39% independent of dose or time on treatment* Heavily Pretreated § PRN1008 showed 10/25 (40%) heavily pretreated 40% (≥4 Prior Therapies) (n=25) patients responding (≥ 4 prior th

  12. Slide 12: PRN1008 Treatment Was Well-Tolerated in ITP Patients

    PRN1008 Treatment Was Well-Tolerated in ITP Patients (N = 31) § Median treatment duration at data cut-off Related TEAEs was 12.0 weeks (range, 0.1-41.9) Grade 1/2 (≥ 2 Patients), n (%) § Related TEAEs were reported in 11 patients All TEAEs 11 (35) (35%); all were grade 1 or 2 Nausea 8 (26) § No trea

  13. Slide 13: Unrelated Serious Adverse Events (Grade 2-3)

    Unrelated Serious Adverse Events (Grade 2-3) Patient Serious Adverse Event Description Rectal hemorrhage, grade 2 Patient was discontinued from the study because rescue medications were used during 0211-003 Start: study day 37, 400 mg bid hospitalization. 9 9 Stop: study day 42 Platelet counts: 16×1

  14. Slide 14: Conclusions

    Conclusions § 54% primary endpoint response rate with bid doses for ≥ 12 weeks − Overall 39% response rate in all patients with median of 6 prior therapies (55% had received prior TPO-RA) § Rapid onset (platelet counts > 30K by the first week of treatment) § Responses were durable in the majority of

Principia Biopharma — Technical Presentation (December 2019) on 6ix